Treatment with CBR agonist delta-tetrahydrocannabinol (THC) or R (+)WIN55212-2 reduced cerebral infarction, neuronal loss, and neurological deficits in experimental stroke animals [11–13]. This evidence concerns the gene CNR1 and stroke disorder.